Abstract
Objective
This study reports the initial results of hypofractionated radiation therapy (HFRT) with concurrent/adjuvant temozolomide (TMZ) for glioblastoma multiforme (GBM) patients with especially poor prognoses.
Methods
Sixteen patients with GBM and Radiation Therapy and Oncology Group (RTOG) recursive partitioning analysis (RPA) class V who underwent maximally safe resection or biopsy (when considered inoperable), followed by HFRT/TMZ, during 2011–2014 were analyzed. HFRT was given in six treatments over 2 weeks using dose painting: 6 × 6 Gy to contrast-enhancing tumor + 5 mm (CTV1) and 6 × 4 Gy to FLAIR hypersignal + 2 cm (CTV2), plus 5-mm expansion for both PTVs. HFRT was delivered concomitantly with TMZ (75 mg/m2 daily), followed by adjuvant TMZ (150–200 mg/m2 in 5/28 days).
Results
Median age was 65 years (50–82) and Karnofsky performance status (KPS) was 60 (40–80). Median pre-op gross tumor maximum dimension on MRI was 4.8 cm (1.8–8.5 cm). Four patients had gross total resection, six had subtotal resection, and six had biopsy only. The treatment was well tolerated without non-hematologic grade 3/4 acute toxicities. No increase in dexamethasone dosage was required in any of the patients during HFRT. With a median follow-up of 9 months (1–28), there were 12 (75 %) recurrences/progressions and 6 (38 %) deaths. Yet, 6 (38 %) patients exceeded survival of 1 year, and 4 were alive as of the latest follow-up at 12, 14, 27, and 28 months. Median survival was 14 months, while median progression-free survival was 5 months.
Conclusion
The HFRT/TMZ regimen was safe, well tolerated, and convenient for GBM patients with the poorest prognosis, rendering a shorter overall treatment time and no increase in toxicity.
Similar content being viewed by others
References
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
Stupp R, Hegi M, Mason W et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
Mirimanoff RO, Gloria T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16):2563–2569
Curran WJ, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85(9):704–710
Li J, Wang M, Won M et al (2010) Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81(3):623–630
Beal K, Omuro A, Karimi S, et al. (2011) Phase II study of bevacizumab (BEV), temozolomide (TMZ) and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). ASTRO. Abstract#260
U. S. Department of Health Services, National Institute of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). HYPERLINK “http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf” http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
Macdonald DR, Cascino TL, Schold SC, Cairncross G (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280
Keime-Guibert F, Chinot O, Tallandier L et al (2007) Radiotherapy for glioblastoma in the elderly. NEJM 356(15):1527–1535
Laigle-Donadey F, Figarella-Branger D, Chinot O et al (2010) Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol 99(1):89–94
Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715
Roa W, Brasher PMA, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588
Malmstrom A, Grenberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926
Ciammella P, Galeandro M, D’Abbiero N et al (2013) Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. Clin Neurol Neurosurg 115(9):1609–1614
Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 91:95–100
Reddy K, Damek D, Gaspar LE et al (2012) Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 84(3):655–660
Reddy K, Gaspar LE, Kavanagh BD et al (2013) Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol 114:111–116
Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR (2012) Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. J Neurooncol 107:395–405
Terasaki M, Eto T, Nakashima S et al (2011) A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neurooncol 102:247–253
Conflict of interest
All authors of this manuscript, Jason C. Ye, Menachem Yondorf, Susan C. Pannullo, John A. Boockvar, Philip E. Stieg, Theodore H. Schwartz, Ronald J. Scheff, Bhupesh Parashar, Dattatreyudu Nori, K.S. Clifford Chao, A.Gabriella Wernicke, declare that they have no conflict of interest to report.
Ethics statement
The study has been approved by the institutional review board. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Statement of informed consent
Informed consent was obtained from all patients for being treated with the alternate regimen and to be included in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ye, J.C., Yondorf, M., Pannullo, S.C. et al. Hypofractionated radiotherapy with concurrent temozolomide chemotherapy in patients with newly diagnosed RPA class V glioblastoma multiforme: promising early results. J Radiat Oncol 4, 19–27 (2015). https://doi.org/10.1007/s13566-014-0180-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13566-014-0180-5